AstraZeneca's stomach cancer drug cuts death risk 53% vs. chemo in late-stage trial
As seen on the 24/7 Wall St. homepage on October 26, 2026.
A 53% cut in death risk versus chemotherapy is the kind of late-stage result that resets an oncology franchise, and it lands after a stretch of pipeline setbacks weighed on the shares. Watch for the full trial data and filing timeline.
BREAKING: AstraZeneca reports major breakthrough in stomach cancer treatment, with its experimental drug reducing the risk of death by 53% compared with chemotherapy in a late-stage trial.
- Replies24
- Reposts31
- Likes237
Continue ReadingShow less
AstraZeneca's experimental stomach cancer drug posted a 53% reduction in the risk of death compared with chemotherapy in a late-stage trial, a result that marks a significant shift in how advanced stomach cancer is treated.
A survival benefit of this magnitude against the chemotherapy standard of care is rarely seen in late-stage oncology trials, and results of this size tend to attract rapid regulatory attention and reshape commercial expectations for an entire therapy area.
The data lands at a moment when AstraZeneca's pipeline has faced pressure, making a result of this scale particularly meaningful for the oncology franchise. Investors will want to focus on when the full trial dataset is published and what the company signals about its filing timeline with regulators.
The next concrete milestone to follow is AstraZeneca's formal submission to regulators and any accelerated review designation, either of which would sharpen the timeline for this drug reaching patients and the market.
Mentioned: AZN